Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $117.0 million.

  • Arcus Biosciences' Non-Current Assets fell 32.37% to $117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.0 million, marking a year-over-year decrease of 32.37%. This contributed to the annual value of $134.0 million for FY2024, which is 49.24% down from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Non-Current Assets is $117.0 million, which was down 9.30% from $129.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Non-Current Assets ranged from a high of $330.0 million in Q4 2021 and a low of $93.2 million during Q1 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $178.0 million (2024), whereas its average is $194.4 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 2,018.78% in 2021, then plummeted by 49.24% in 2024.
  • Over the past 5 years, Arcus Biosciences' Non-Current Assets (Quarterly) stood at $330.0 million in 2021, then decreased by 29.39% to $233.0 million in 2022, then rose by 13.30% to $264.0 million in 2023, then slumped by 49.24% to $134.0 million in 2024, then crashed by 32.37% to $117.0 million in 2025.
  • Its last three reported values are $117.0 million in Q3 2025, $129.0 million for Q2 2025, and $125.0 million during Q1 2025.